Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
- 13 December 2006
- journal article
- review article
- Published by Elsevier BV in Steroids
- Vol. 72 (1), 7-25
- https://doi.org/10.1016/j.steroids.2006.10.009
Abstract
No abstract availableKeywords
This publication has 145 references indexed in Scilit:
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Antagonism of estrogen action with a new benzothiophene derived antiestrogenLife Sciences, 1983
- Aromatase inhibitors—iv. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dioneThe Journal of Steroid Biochemistry and Molecular Biology, 1979
- Studies on the mechanism of estrogen biosynthesis in the rat ovary–IThe Journal of Steroid Biochemistry and Molecular Biology, 1976
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971